Sloan Sheldon 4
4 · Spyre Therapeutics, Inc. · Filed Oct 1, 2024
Insider Transaction Report
Form 4
Sloan Sheldon
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-10-01+400,000→ 400,000 totalExercise: $27.46Exp: 2034-10-01→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.